Investor Relations

Dec 22, 2024 12:55 PM EST

Minimum 15 minutes delayed. Source: LSEG

Date	Title
Dec 09, 2024	Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Dec 06, 2024	Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 11, 2024	Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Nov 07, 2024	Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

Date	Title
Dec 10, 2024	Chimerix Corporate Presentation 3.1 MB

SEC FILINGS

Filing date	Form	Description	View
Nov 26, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-054117.pdf 0001209191-13-054117.rtf 0001209191-13-054117.xls
Nov 25, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-054021.pdf 0001209191-13-054021.rtf 0001209191-13-054021.xls
Nov 22, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-053750.pdf 0001209191-13-053750.rtf 0001209191-13-053750.xls
Nov 20, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-053362.pdf 0001209191-13-053362.rtf 0001209191-13-053362.xls
Nov 19, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-053041.pdf 0001209191-13-053041.rtf 0001209191-13-053041.xls
Nov 19, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-053039.pdf 0001209191-13-053039.rtf 0001209191-13-053039.xls
Nov 19, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-053042.pdf 0001209191-13-053042.rtf 0001209191-13-053042.xls
Nov 19, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001209191-13-053146.pdf 0001209191-13-053146.rtf 0001209191-13-053146.xls
Nov 15, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001144204-13-062517.pdf 0001144204-13-062517.rtf 0001144204-13-062517.xls
Nov 15, 2013	4	Statement of changes in beneficial ownership of securities	View HTML 0001144204-13-062521.pdf 0001144204-13-062521.rtf 0001144204-13-062521.xls

On what stock exchange are Chimerix shares traded, and what is the ticker symbol?

The Chimerix ticker is CMRX and it is traded on the Nasdaq Global Market.

Where is Chimerix's corporate headquarters?

2505 Meridian Parkway, Suite 100, Durham, NC 27713

Who are the members of Chimerix's Board of Directors?

You can view our Board of Directors by visiting the Board of Directors section of our Investor Relations website.

Who are the members of the Chimerix's management team?

You can view our management team by visiting the Management section of our Investor Relations website.

When does Chimerix's fiscal year end?

December 31

Does Chimerix pay dividends?

Chimerix does not expect to declare or pay any cash or other dividends on our common stock.

Does Chimerix have a direct stock purchase plan?

Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financial Information portion of our Investor Relations website or directly from the SEC at www.sec.gov.

Who is Chimerix's transfer agent and who do I contact with questions about my stock certificates? How can I contact Chimerix's transfer agent?

The transfer agent and registrar for our common stock is: Computershare Trust Company, N.A. The transfer agent and registrar’s address is: P.O. Box 43078 Providence, Rhode Island 02940

Date	Details
Dec 10, 2024 at 8:30 AM EST	Regulatory Update Call Listen to Webcast
Nov 7, 2024 at 8:30 AM EST	Chimerix Q3 2024 Earnings Conference Call Listen to Webcast
Sep 9, 2024 at 7:00 AM EDT	HC Wainwright 26th Annual Global Investment Conference Listen to Webcast

Oncology

Press Releases

Presentations

Upcoming Events

SEC FILINGS

FAQ

Archived Events

QUARTERLY RESULTS